English, Article edition: Infliximab: A Pharmacoeconomic Review of its Use in Rheumatoid Arthritis Katherine A. Lyseng-Williamson; Rachel H. Foster

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94472
Physical Description
  • article
Language
  • English

Edition details

Title
  • Infliximab: A Pharmacoeconomic Review of its Use in Rheumatoid Arthritis
Author
  • Katherine A. Lyseng-Williamson
  • Rachel H. Foster
Physical Description
  • article
Notes
  • Infliximab (Remicade(R)), a biological disease-modifying antirheumatic drug (DMARD), binds to and inhibits the activity of tumour necrosis factor-alpha, which is thought to play an important role in the pathophysiology of rheumatoid arthritis. Intravenous infliximab plus methotrexate is recommended in patients with rheumatoid arthritis who have not achieved satisfactory disease control with adequate courses of other DMARDs. Pharmacoeconomic analyses have been based on efficacy data from the pivotal placebo-controlled Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) trial in patients with active, refractory rheumatoid arthritis. Infliximab every 8 weeks plus methotrexate demonstrated rapid and sustainable improvements in clinical response, delayed radiographic progression, and/​or improved functional status and health-related QOL compared with placebo plus methotrexate at weeks 30, 54 and 102. In cost-utility analyses of infliximab plus methotrexate conducted from a healthcare payer and/​or societal perspective in the US, Europe, Portugal, Sweden and the UK, infliximab 3 mg/​kg every 8 weeks plus methotrexate was associated with acceptable (<$US50 In conclusion, cost-utility analyses, which were based on modelling of data from the pivotal clinical trial of infliximab plus methotrexate, indicate that infliximab plus methotrexate is associated with acceptable cost-effectiveness ratios (<$US50
  • Adis-Drug-Evaluations, Anti-TNF-alpha-monoclonal-antibody, Cost-analysis, Disease-modifying-antirheumatics, Infliximab, Quality-of-life, Rheumatoid-arthritis
  • RePEc:wkh:phecon:v:22:y:2004:i:2:p:107-132
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment